$LTRN

Lantern Pharma (NASDAQ: LTRN) said the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent covering patient selection and treatment for ovarian, primary liver, kidney and thyroid cancers using LP-184 (zirdafulven). The allowed claims relate to a three-gene biomarker signature (PTGR1, PTPN14, ASPH). Lantern cited a 45% disease control rate at or above the effective dose in Phase 1a and plans multiple Phase 1b/2 studies in 2026.

New to The Street said its Bloomberg Television sponsored program airs May 30 at 6:30 PM ET, featuring interviews with executives across AI, healthcare, fintech, digital assets and commodities. Among guests: YesSmile.ai (AI for dental admin in a $200B market), Lantern Pharma (Zeta for rare cancers), Roadzen (AI for auto insurance), and Gold Royalty Corp. (250+ royalties/streams).

RedChip Companies will broadcast interviews with Enlivex Therapeutics (Nasdaq: ENLV) and Lantern Pharma (Nasdaq: LTRN) on its "RedChip Small Stocks, Big Money™" show on Bloomberg TV this Saturday, October 4th, at 7 p.m. ET. The interviews will cover Enlivex's positive Phase IIa results for Allocetra™ in knee osteoarthritis and Lantern Pharma's AI and machine learning platform, RADR®, for cancer drug discovery and development. Both companies will discuss their clinical pipelines and future development plans.

US-based Lantern Pharma Inc., a company focused on AI-driven precision oncology, has announced the opening of an AI Centre of Excellence and Advanced Agentic Labs in Bengaluru, India. This initiative aims to scale up Lantern's AI platform globally, expanding its computational capacity and technical talent. The center will support both Lantern's internal pipeline and collaborations, enhancing its proprietary RADR® AI platform and accelerating the development of specialized large language models and quantitative models for drug discovery.

Lantern Pharma ( NASDAQ:LTRN ) , a biotech focused on AI-enabled precision oncology, released its earnings for the quarter ended June 30, 2025, on August 13, 2025. Lantern Pharma reported a GAAP net loss per share of ( $0.40 ) in Q2 2025, and marking an improvement from ( $0.46 ) per share ( GAAP ...

AUSTIN, Texas, July 16, 2025 ( GLOBE NEWSWIRE ) -- via IBN -- Lantern Pharma Inc.

FDA clears Lantern's IND for LP-184 in Phase 1b/2 trial targeting advanced-stage triple-negative breast cancer. Trial includes LP-184 monotherapy and combo with olaparib for BRCA1/2-altered TNBC in second-line settings.